/CNW/ - Johnson & Johnson (NYSE: JNJ) announced today that Health Canada has issued a Notice of Compliance (NOC) for CARVYKTI® (ciltacabtagene autoleucel) for...
J&J JNJ stock has plunged 6.1% in a month, losing almost $24 billion of its market value.Though slowing sales in its MedTech segment, the upcoming patent expiration of its blockbuster drug, Stelara, and...
MicroStrategy stock has gained close to 3,000% since the company started holding Bitcoin on its balance sheet more than four years ago.
ORIC Pharmaceuticals is a stock analyst price targets currently signal double-bagger potential in. See what the excitement around this firm is all about.
These three companies all have one thing in common: they are all on sale.
The third-quarter earnings season came to an end this week for large drugmakers, with AstraZeneca AZN and Bayer BAYRY announcing their results. AbbVie’s ABBV schizophrenia candidate, added from a recent...
Stocks in these "safe" sectors are selling off as investors gravitate toward growth.
Bayer AG BAYRY reported third-quarter 2024 core earnings of 7 cents per American Depositary Receipt (ADR), which missed the Zacks Consensus Estimate of 17 cents. The company reported earnings of 10 cents...
Shares of Intuitive Surgical ISRG have risen 9.9% in the past month against the Zacks Medical - Instruments industry’s decline of 1% and the broader Zacks Medical sector’s fall of 3.2%. The S&P 500...
/Johnson%20%26%20Johnson%20logo%20on%20phone-by%20Allmy%20via%20Shutterstock.jpg)
Johnson & Johnson has struggled to keep up with the broader market over the past year, and analysts are cautiously bullish on its future potential.